Eptifibatide (Integrilin)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: reversibly inhibits the glycoprotein IIb/IIIa receptor on platelets, preventing them from binding to fibrinogen, von Willebrand factor, and other adhesion molecules and thereby inhibiting platelet aggregation.
Route: IV
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias or the prescribing information.

Also known as

  • Brand name: Integrilin